NASDAQ · JSPR
Jasper Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for JSPR: Nov 9, 2026
Jasper Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-1.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $0.16 | $-0.32 | 3 |
| Dec 2026 | $-0.30 | $-0.02 | $-0.46 | 3 |
| Mar 2027 | $-0.03 | $-0.02 | $-0.03 | 2 |
| Jun 2027 | $-0.03 | $-0.02 | $-0.03 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 15, 10:31 AM EDTJasper Therapeutics Nears IgAN Data Readout, Plans FSGS Study In 2027(RTTNews) – On Thursday, Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, announced completion of enrollment in the first cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).
- Fintel · Oct 2, 3:24 PM EDTJasper Therapeutics Consensus Price Target Increased 19.86% to $8.92The average one-year price target for Jasper Therapeutics (NASDAQCM:JSPR) has been revised to $8.92 / share. This is an increase of 19.86% from the prior estimate of $7.45 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources
- RTTNews · Sep 16, 3:15 AM EDTJasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock Up(RTTNews) – Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, announced the appointments of Lisa Pitt as Senior Vice President, Regulatory Affairs and Shiguang Liu as Vice President, Clinical Development.
- RTTNews · Aug 14, 12:29 PM EDTJasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline(RTTNews) – Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals.
- RTTNews · Jul 17, 4:30 AM EDTJasper Completes Kira Acquisition, Eyes Multiple Clinical Milestones Through 2027; Stock Down(RTTNews) – Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, announced that it has completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. In addition, the company provided an update on the near-term milestones as a combined company
- Zacks · Jun 3, 9:55 AM EDTBears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' NowJasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for
- Zacks · May 27, 9:58 AM EDTFDA Extends Review Time for AZN's Camizestrant Combo in Breast CancerAstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
- Zacks · May 25, 11:37 AM EDTAZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid TumorsAstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
- Zacks · May 25, 11:30 AM EDTAZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast CancerAstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
- RTTNews · Dec 2, 8:08 AM ESTJasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study(RTTNews) – Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, on Tuesday reported encouraging preliminary data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adults with allergic asthma.
- RTTNews · Dec 2, 4:38 AM ESTJasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results(RTTNews) – Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company, is set to host a webinar to present findings from its BEACON study in chronic spontaneous urticaria, along with preliminary data from the ETESIAN study in asthma, on December 2, 2025.
- RTTNews · Dec 1, 11:02 PM ESTAfter-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close(RTTNews) – Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Jasper Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.